telephone:+7 (8352) 222-490
Mail:info@interactive-plus.ru
rus eng


  1. Main
  2. Journal "Interactive science"
  3. No 5 (15)
  4. Synthetic cathinone “bath salts”: the mechanism of...
Центр научного сотрудничества "Интерактив плюс"
info@interactive-plus.ru
+7 (8352) 222-490
2130122532
Центр научного сотрудничества «Интерактив плюс»
RU
428000
Чувашская Республика
г.Чебоксары
ул.Гражданская, д.75
428000, Россия, Чувашская Республика, г. Чебоксары, улица Гражданская, дом 75
+7 (8352) 222-490
RU
428000
Чувашская Республика
г.Чебоксары
ул.Гражданская, д.75
56.125001
47.208966

Synthetic cathinone “bath salts”: the mechanism of action, toxicological aspects, clinic, dependence development

Research Article
DOI: 10.21661/r-130075
Open Access
Monthly international academic journal «Interactive science»
Creative commons logo
Published in:
Monthly international academic journal «Interactive science»
Author:
Antsyborov A.V. 1
Scientific adviser:
Mrykhin V.V.2
Work direction:
Медицина
Rating:
Article accesses:
9332
Published in:
doaj
eLibrary.ru
Cited by:
2 articles
1 Mental Health Clinic «Psyche»
2 FSFEI of HE “Rostov State Medical University” of Russian Ministry of Health
For citation:
Antsyborov A. V. (2017). Synthetic cathinone “bath salts”: the mechanism of action, toxicological aspects, clinic, dependence development. Interactive science, 29-39. https://doi.org/10.21661/r-130075
  • Metadata
  • Full text
  • Metrics
  • Related articles
  • Cited by
UDC 61

Abstract

According to the authors synthetic cathinone is a new class of designer drugs with psychoactive effect at the peak of intoxication which can cause hallucinatory disorders, acute paranoid disorders of psychotic level, the development of delirious disorders, affective disorders comparable to cocaine, methylenedioxymethamphetamine (MDMA) and other drugs with amphetamine-like effect. The first reports of synthetic cathinone appeared in early 2009. On the black market, these substances were marketed as «bath salts». The legislation of the European countries have been carrying these substances to the drug since 2010, in the United States synthetic cathinone has been included in the list of narcotic substances since 2011, in the Russian Federation, these substances can be attributed to narcotic according to the Decree of the RF Government dated 31 December 2009 №1186 «About modification of some resolutions of the Government of the Russian Federation on issues related to trafficking in narcotic drugs». Recent clinical studies indicate dysregulation effect of synthetic cathinone’s on central monoamine system, which is one of the main mechanisms of synthetic cathinone’s action, and is the basis of behavioral disorders due to use. The review provides data about the chemical structure of synthetic cathinone’s, mechanisms of addiction, toxicology, clinical aspects of use.

References

  1. 1. Ziporyn T. A growing industry and menace: makeshift laboratory's designer drugs // JAMA: The Journal of the American Medical Association. [PubMed: 3491222]. – 1986. – №256. – Р. 3061–3063.
  2. 2. Henderson GL. Designer drugs: past history and future prospects // Journal of forensic sciences. [PubMed: 3286815]. – 1988. – №33. – Р. 569–575
  3. 3. Kram TC, Cooper DA, Allen AC. Behind the identification of China White. Analytical chemistry. – 1981. – 53:1379A-1386A.
  4. 4. Freudenmann RW, Oxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. [PubMed: 16911722]. – 2006. – №101. – Р. 1241–1245.
  5. 5. Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R, et al. Purchasing 'legal highs' on the Internet--is there consistency in what you get? / QJM: monthly journal of the Association of Physicians. [PubMed: 20413562]. 2010. – №103. – Р. 489–493.
  6. 6. Sanchez SdB. Sur un homologue de l'ephedrine. Bulletin de la Société Chimique de France. – 1929.
  7. 7. Emerson TS, Cisek JE. Methcathinone: a Russian designer amphetamine infiltrates the rural midwest. Annals of emergency medicine. [PubMed: 8239113]. – 1993. – №22. – Р. 1897–1903.
  8. 8. Jacob Peyton III ATS. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones. In: Office EP., editor. – 1996. – C07D317/66 ed.
  9. 9. G.m.b.H. BI. 1-(3',4'-methylenedioxy-phenyl)-2-pyrrolidino-alkanones-(1). In: Office USP., editor. – United States, 1967.
  10. 10. Morris H. Mephedrone: The Phantom Menace. Vice. – 2010. – Р. 98–100.
  11. 11. BBC. New 'legal high' arrives in area. British Broadcasting Corporation. – 2009.
  12. 12. Wood DM, Hunter L, Measham F, Dargan PI. Limited use of novel psychoactive substances in South London nightclubs // QJM: monthly journal of the Association of Physicians. [PubMed: 22718853]. – 2012. – №105. – Р. 959–964.
  13. 13. Brunt TM, Poortman A, Niesink RJ, van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. Journal of psychopharmacology. [PubMed: 20826554]. – 2011. – №25. – Р. 1543–1547.
  14. 14. Addiction EMCfDaD. Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances. – Luxembourg: The Publications Office of the European Union. – 2011. – №193.
  15. 15. Kasick DP, McKnight CA, Klisovic E. «Bath salt» ingestion leading to severe intoxication delirium: two cases and a brief review of the emergence of mephedrone use. The American journal of drug and alcohol abuse. [PubMed: 22221190]. – 2012. – № 38. – Р. 176–180.
  16. 16. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J. Mephedrone: use, subjective effects and health risks. Addiction. [PubMed: 21592252]. – 2011. – № 106. – Р. 1991–1996.
  17. 17. Kavanagh P, O'Brien J, Power JD, Talbot B, McDermott SD. 'Smoking' mephedrone: The identification of the pyrolysis products of 4-methylmethcathinone hydrochloride. Drug testing and analysis. – 2012.
  18. 18. James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP, et al. Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emergency medicine journal: EMJ. [PubMed: 20798084]. – 2011. – №28. – Р. 686–689.
  19. 19. Dargan PI, Albert S, Wood DM. Mephedrone use and associated adverse effects in school and college / university students before the UK legislation change. QJM: monthly journal of the Association of Physicians. [PubMed: 20675396]. – 2010. – №103. – Р. 875–879.
  20. 20. Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4- methylmethcathinone, «meow meow») in the United Kingdom // Journal of clinical psychopharmacology. [PubMed: 22926609]. – 2012. – № 32. – Р. 710–714.
  21. 21. U.S. Drug Enforcement Administration OoDC. National Forensic Laboratory Information System: Year 2011 Annual Report. In: Administration USDE., editor. – Springfield, VA, 2012.
  22. 22. Centers AAoPC., editor. Centers AAoPC. Bath Salts Data. – 2012.
  23. 23. Wiegand TJ, Wax PM, Schwartz T, Finkelstein Y, Gorodetsky R, Brent J, et al. The Toxicology Investigators Consortium Case Registry – the 2011 experience // Journal of medical toxicology: official journal of the American College of Medical Toxicology. [PubMed: 23055123]. – 2012. – №8. – Р. 360–377.
  24. 24. Carhart-Harris RL, King LA, Nutt DJ. A web-based survey on mephedrone. Drug and alcohol dependence. [PubMed: 21420252]. – 2011. – №118. – Р. 19–22.
  25. 25. Freeman TP, Morgan CJ, Vaughn-Jones J, Hussain N, Karimi K, Curran HV. Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Addiction. [PubMed: 22257011]. – 2012. – №107. – Р. 792–800.
  26. 26. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annual review of pharmacology and toxicology. – 2007. – №47. – Р. 681–698.
  27. 27. Connor CE, Kuczenski R. Evidence that amphetamine and Na+ gradient reversal increase striatal synaptosomal dopamine synthesis through carrier-mediated efflux of dopamine. Biochemical pharmacology. [PubMed: 3092833]. – 1986. – №35. – Р. 3123–3130.
  28. 28. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proceedings of the National Academy of Sciences of the United States of America. [PubMed: 15728379]. – 2005. – №102. – Р. 3495–3500.
  29. 29. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse / The Journal of pharmacology and experimental therapeutics [PubMed: 21810934]. – 2011. – №339. – Р. 530–536.
  30. 30. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [PubMed: 22169943]. – 2012a. – №37. – Р. 1192–1203.
  31. 31. Martinez-Clemente J, Escubedo E, Pubill D, Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. [PubMed: 21824752]. – 2012. – №22. – Р. 231–236.
  32. 32. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. Powerful Cocaine – Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive 'Bath Salts' Products. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. – 2012b.
  33. 33. Cameron KN, Kolanos R, Solis E, Glennon RA, De Felice LJ. Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. British journal of pharmacology. – 2012.
  34. 34. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, et al. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. British journal of pharmacology. [PubMed: 21615721]. – 2011. – №164. – Р. 1949–1958.
  35. 35. den Hollander B, Rozov S, Linden AM, Uusi-Oukari M, Ojanpera I, Korpi ER. Long-term cognitive and neurochemical effects of «bath salt» designer drugs methylone and mephedrone. Pharmacology, biochemistry, and behavior. – 2013. – №103. – 501–509.
  36. 36. Motbey CP, Karanges E, Li KM, Wilkinson S, Winstock AR, Ramsay J, et al. Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion. PloS one. [PubMed: 23029034]. – 2012. – №7: e45473.
  37. 37. Angoa-Perez M, Kane MJ, Francescutti DM, Sykes KE, Shah MM, Mohammed AM, et al. Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. Journal of neurochemistry. [PubMed: 22191803]. – 2012b. – №20. – Р. 1097–1107.
  38. 38. Bowyer JF, Robinson B, Ali S, Schmued LC. Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure. Synapse. [PubMed: 18081184]. – 2008. – №62. – Р. 193–204.
  39. 39. Fleckenstein AE, Metzger RR, Beyeler ML, Gibb JW, Hanson GR. Oxygen radicals diminish dopamine transporter function in rat striatum. European journal of pharmacology. [PubMed: 9346337]. – 1997a. – №334. – Р. 111–114.
  40. 40. Fleckenstein AE, Wilkins DG, Gibb JW, Hanson GR. Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. The Journal of pharmacology and experimental therapeutics. [PubMed: 9336334]. – 1997b. – №283. – Р. 281–285.
  41. 41. LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci. [PubMed: 9952424]. – 1999. – №19. – Р. 1484–1491.
  42. 42. Aarde SM, Angrish D, Barlow DJ, Wright MJ Jr, Vandewater SA, Creehan KM, et al. Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addiction biology. – 2013.
  43. 43. Miller ML, Creehan KM, Angrish D, Barlow DJ, Houseknecht KL, Dickerson TJ, et al. Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). Drug and alcohol dependence. [PubMed: 22832282]. – 2013. – №127. – Р. 248–253.
  44. 44. Wright MJ Jr, Angrish D, Aarde SM, Barlow DJ, Buczynski MW, Creehan KM, et al. Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4- methylmethcathinone in Wistar and Sprague-Dawley rats. PloS one. [PubMed: 22952999]. – 2012a. – №7: e44652.
  45. 45. Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of «bath salts» containing 3,4-methylenedioxypyrovalerone. Annals of emergency medicine. [PubMed: 22387085]. – 2012. – №60. – Р. 103–105.
  46. 46. Forrester MB. Adolescent synthetic cathinone exposures reported to Texas poison centers. Pediatric emergency care. [PubMed: 23364377]. – 2013. – №29. – Р. 151–155.
  47. 47. Levine M, Levitan R, Skolnik A. Compartment Syndrome After «Bath Salts» Use: A Case Series. Annals of emergency medicine. – 2013.
  48. 48. Ross EA, Reisfield GM, Watson MC, Chronister CW, Goldberger BA. Psychoactive «bath salts» intoxication with methylenedioxypyrovalerone. The American journal of medicine. [PubMed: 22682791]. 2012. – №125. – Р. 854–858.
  49. 49. Angoa-Perez M, Kane MJ, Briggs DI, Francescutti DM, Sykes CE, Shah MM, et al. Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. Journal of neurochemistry. – 2012a.
  50. 50. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annual review of medicine. – 2009. – №60. – Р. 355–366.
  51. 51. Fantegrossi WE, Gannon BM, Zimmerman SM, Rice KC. In vivo Effects of Abused 'Bath Salt' Constituent 3,4-methylenedioxypyrovalerone (MDPV) in Mice: Drug Discrimination, Thermoregulation, and Locomotor Activity. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. – 2012.
  52. 52. Marusich JA, Grant KR, Blough BE, Wiley JL. Effects of synthetic cathinones contained in «bath salts» on motor behavior and a functional observational battery in mice. Neurotoxicology. [PubMed: 22922498]. – 2012. – №33. – Р. 1305–1313.
  53. 53. Huang PK, Aarde SM, Angrish D, Houseknecht KL, Dickerson TJ, Taffe MA. Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug and alcohol dependence. [PubMed: 22664136]. – 2012. – №126. – Р. 168–175.
  54. 54. Klinker F, Hasan K, Paulus W, Nitsche MA, Liebetanz D. Pharmacological blockade and genetic absence of the dopamine D2 receptor specifically modulate voluntary locomotor activity in mice. Behavioural brain research. [PubMed: 23291158]. – 2013. – №242C:117–124.
  55. 55. Wright MJ Jr, Vandewater SA, Angrish D, Dickerson TJ, Taffe MA. Mephedrone (4- methylmethcathinone) and d-methamphetamine improve visuospatial associative memory, but not spatial working memory, in rhesus macaques. British journal of pharmacology. [PubMed: 22748013]. – 2012b. – №167. – Р. 1342–1352.
  56. 56. Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, et al. Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addiction biology. – 2012.
  57. 57. Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of «bath salts» and «legal highs» (synthetic cathinones) in the United States. Clinical toxicology. [PubMed: 21824061]. – 2011. – №49. Р. 499–505.
  58. 58. Stoica MV, Felthous AR. Acute Psychosis Induced by Bath Salts: A Case Report with Clinical and Forensic Implications. Journal of forensic sciences. – 2013.
  59. 59. Thornton SL, Gerona RR, Tomaszewski CA. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. Journal of medical toxicology: official journal of the American College of Medical Toxicology. [PubMed: 22528592]. – 2012. – №8. – Р. 310–313.
  60. 60. Mas-Morey P, Visser MH, Winkelmolen L, Touw DJ. Clinical Toxicology and Management of Intoxications with Synthetic Cathinones («Bath Salts»). Journal of pharmacy practice. – 2012.
  61. 61. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta psychiatrica Scandinavica. [PubMed: 2873715]. – 1986. – №73. – Р. 337–347
  62. 62. Adebamiro A, Perazella MA. Recurrent acute kidney injury following bath salts intoxication. American journal of kidney diseases: the official journal of the National Kidney Foundation. [PubMed: 22119408]. – 2012. – №59. – Р. 273–275.
  63. 63. Aromatario M, Bottoni E, Santoni M, Ciallella C. New «lethal highs»: a case of a deadly cocktail of GHB and Mephedrone. Forensic science international. [PubMed: 23088826]. – 2012. –№223: e38-e41.
  64. 64. Marinetti LJ, Antonides HM. Analysis of Synthetic Cathinones Commonly Found in Bath Salts in Human Performance and Postmortem Toxicology: Method Development, Drug Distribution and Interpretation of Results. Journal of analytical toxicology. – 2013.
  65. 65. Maskell PD, De Paoli G, Seneviratne C, Pounder DJ. Mephedrone (4-methylmethcathinone)-related deaths. Journal of analytical toxicology. [PubMed: 21439157]. – 2011. – №35. – Р. 188–191.
  66. 66. Wagner GC, Avena N, Kita T, Nakashima T, Fisher H, Halladay AK. Risperidone reduction of amphetamine-induced self-injurious behavior in mice. Neuropharmacology. [PubMed: 14996547]. – 2004. – №46. – Р. 700–708.
  67. 67. Services NH., editor. Statistics on Drug Misuse: England. England: 2011. The NHS Information Centre LS. – 2011.
  68. 68. Wood DM, Stribley V, Dargan PI, Davies S, Holt DW, Ramsey J. Variability in the 3,4-methylenedioxymethamphetamine content of 'ecstasy' tablets in the UK. Emergency medicine journal: EMJ. [PubMed: 20724467]. – 2011. – №28. – Р. 764–765.
  69. 69. Meng H, Cao J, Kang J, Ying X, Ji J, Reynolds W, et al. Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat. Toxicology letters. [PubMed: 22037396]. – 2012. – №208. – Р. 62–68.
  70. 70. Shishido T, Watanabe Y, Kato K, Horikoshi R, Niwa SI. Effects of dopamine, NMDA, opiate, and serotonin-related agents on acute methamphetamine-induced self-injurious behavior in mice. Pharmacology, biochemistry, and behavior. – 2000. – №66. – Р. 579–583.
  71. 71. Robinson JE, Agoglia AE, Fish EW, Krouse MC, Malanga CJ. Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J mice: comparison to cocaine. Behavioural brain research. [PubMed: 22728726]. – 2012. – №234. Р. 76–81.
  72. 72. Administration USDE., editor. U.S. Drug Enforcement Administration OoDC. National Forensic Laboratory Information System Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS. – 2009–2010; 2011.
  73. 73. Gebissa E. Khat in the Horn of Africa: historical perspectives and current trends. Journal of ethnopharmacology. [PubMed: 20227478]. – 2010. – №132. – Р. 607–614.
  74. 74. Anti-Drug Abuse Act of 1986. United States of America. – 1986.
  75. 75. Drug Enforcement Administration DoJ. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order. Federal register. – 2011. – №76. – Р. 65371–65375.
  76. 76. Karch’s Pathology
of Drug Abuse Fifth Edition 2016 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business.
  77. 77. Мрыхин В.В. Психиатрические аспекты употребления дизайнерских наркотиков и новых психоактивных веществ[Текст] / В.В. Мрыхин, А.В. Анцыборов // Интерактивная наука. – 2017. – №12. – С. 64–74.
  78. 78. Асадуллин А.Р. Approach to Classifying «Design» Drugs and New Potentially Dangerous Chemical Substances, With a Brief Review of the Problem / А.Р. Асадуллин, Е.Х. Галеева, Э. А. Ахметова, И.В. Николаев // International Journal Of Environmental&Science Education. – 2016. – Vol. 11. – №14. – С. 6697–6703.
  79. 79. Асадуллин А.Р. Клинический случай внутривенного употребления метилендиоксипировалерона у пациента с синдромом зависимости от синтетических стимуляторов / А.Р. Асадуллин, В.Л. Юлдашев, Э.А. Ахметова // Неврологический вестник. Журнал имени В.М. Бехтерева. – 2016. – Вып. 2. – С. 63–66.
  80. 80. Асадуллин А.Р. Особенности парентерального употребления метилендиоксипировалерона пациентом с синдромом зависимости от синтетических стимуляторов / А.Р. Асадуллин, В.Л. Юлдашев, Э.А. Ахметова, С.А. Халиков // Медицинский вестник Башкортостана. – 2016. – №4. – С. 87–91.

Comments(0)

When adding a comment stipulate:
  • the relevance of the published material;
  • general estimation (originality and relevance of the topic, completeness, depth, comprehensiveness of topic disclosure, consistency, coherence, evidence, structural ordering, nature and the accuracy of the examples, illustrative material, the credibility of the conclusions;
  • disadvantages, shortcomings;
  • questions and wishes to author.